ALDOA and neoplasm: In addition, LOXL2 catalyses the deacetylation of fructose-bisphosphate aldolase A (ALDOA) at K13, leading to the mobilisation of aldolase A from the cytoskeletal to the cytosolic fraction, which enhances glycolysis and subsequently promotes tumour progression [16].